ANI Pharmaceuticals | ANIP - Current Liabilities


ANI Pharmaceuticals reported $270.56M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
Assertio Holdings USD 166.78M 34.25M Sep/2025
Aurora Cannabis CAD 124.12M 32.76M Sep/2025
Canopy Growth CAD 81.1M 17.56M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Hikma Pharmaceutical USD 2.06B 78M Jun/2025
Knight Therapeutics CAD 118.15M 12.32M Sep/2024
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Novartis USD 32B 286M Sep/2025
Omeros USD 85.5M 2.28M Jun/2025
Perrigo USD 1.15B 19.2M Sep/2025
Sun Pharmaceuticals INR 234.15B 52.21B Sep/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025